Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
resistant potato starch
- Development stage
- Phase 2
- Lead developer
- Manitoba Starch Products
- Modality
- Microbiome Therapeutics
- Administration
- Oral
01
Overview
Resistant potato starch (RPS) is a type of resistant starch (specifically RS2) that resists digestion in the small intestine and ferments in the large intestine. As a prebiotic, it feeds beneficial gut bacteria, promoting the production of short-chain fatty acids, particularly butyrate. Butyrate serves as the preferred fuel for colonic cells and has been associated with various health benefits including improved gut health, reduced inflammation, and enhanced metabolic function. RPS contains approximately 80% resistant starch by weight.
- Brand names
- Bob's Red Mill potato starch
- Other names
- RPSresistant starch type 2RS2RS-2RS 2
Beyond the preview
Go deeper on resistant potato starch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on resistant potato starch.